ArticleDisease markers2022

Afatinib Targeted Therapy Affects the Immune Function and Serum Levels of EGFR and Gastrin-Releasing Peptide Precursor (pro-GRP) in Patients with Non-Small-Cell Lung Cancer (NSCLC).

Wei Cao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.